CVTX - CV Therapeutics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (36)	3/23/2001 12:03:43 PM
From: keokalani'nui	Read Replies (1) of 411

As for side effects, I see that: >>Side effects more common during ranolazine treatment than during placebo treatment included dizziness, nausea, asthenia and constipation. The rate of any adverse event, including these four, was 16% for placebo. The adverse event rate for the 500 mg dose was identical to placebo, and was six percentage points higher than on placebo for the 1000 mg dose. At the 1500 mg dose the adverse event rate was 18 percentage points higher than on placebo.<< But importantly: >>Results of the trial indicated that at each of the three doses studied, ranolazine was associated with statistically significant (p < 0.005) increases in patients' treadmill exercise duration with no clinically meaningful effects on blood pressure or heart rate compared to placebo. <<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next